We are live on
!
Find out more
Parallel Advisors Portfolio holdings
AUM
$6.56B
Turnover
11.49%
1-Year Est. Return
32.24%
This Fund
S&P 500
This Quarter
Est. Return
-4.09%
1 Year Est. Return
+32.24%
3 Year Est. Return
+108.68%
5 Year Est. Return
+114.41%
10 Year Est. Return
–
AUM
$2.52B
AUM Growth
-$173M
(-6.4%)
Cap. Flow
-$49.2M
Cap. Flow
% of AUM
-1.95%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
3,473
New
218
Increased
908
Reduced
1,467
Closed
292
Avg Time Held Equity + Options
3
years
Top 10 Avg Time Held Equity + Options
2.4
years
Top 20 Avg Time Held Equity + Options
2.4
years
Avg Time Held Equity only
3
years
Top 10 Avg Time Held Equity only
2.4
years
Top 20 Avg Time Held Equity only
2.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Fallen Angels USD Bond ETF
FALN
|
+$9.31M |
| 2 |
iShares Core MSCI EAFE ETF
IEFA
|
+$6.87M |
| 3 |
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
|
+$3.6M |
| 4 |
Corcept Therapeutics
CORT
|
+$3M |
| 5 |
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
|
+$2.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard ESG US Stock ETF
ESGV
|
+$9.63M |
| 2 |
iShares Core S&P Total US Stock Market ETF
ITOT
|
+$7.01M |
| 3 |
Microsoft
MSFT
|
+$5.41M |
| 4 |
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
|
+$5.16M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$4.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 51.1% |
| 2 | Technology | 15.39% |
| 3 | Financials | 8.2% |
| 4 | Healthcare | 7.16% |
| 5 | Consumer Discretionary | 5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2951
Algonquin Power & Utilities
AQN
$4B
| $0 | ﹤0.01% |
+8
| New | +$115 |
2022 Q1
0 quarters
|
|
2952
Antero Resources
AR
$11.2B
| $0 | ﹤0.01% |
+4
| New | +$90 |
2022 Q1
0 quarters
|
|
2953
Arcturus Therapeutics
ARCT
$320M
| $0 | ﹤0.01% |
17
-58
| -77% | -$1.48K |
2021 Q1
4 quarters
|
|
2954
Arlo Technologies
ARLO
$1.34B
| – | – |
-17
| Closed | – | – |
|
2955
Academy Sports + Outdoors
ASO
$3.6B
| – | – |
-3
| Closed | – | – |
|
2956
Alphatec Holdings
ATEC
$1.69B
| – | – |
-13
| Closed | – | – |
|
2957
LeonaBio Inc
LONA
$49.8M
| – | – |
-20
| Closed | -$3K | – |
|
2958
Atlanticus Holdings
ATLC
$1.42B
| $0 | ﹤0.01% |
3
| – | – |
2021 Q3
2 quarters
|
|
2959
Atomera
ATOM
$130M
| – | – |
-152
| Closed | -$3K | – |
|
2960
Aurora
AUR
$10.8B
| $0 | ﹤0.01% |
30
| – | – |
2021 Q3
2 quarters
|
|
2961
Avista
AVA
$3.03B
| $0 | ﹤0.01% |
6
| – | – |
2021 Q3
2 quarters
|
|
2962
Atea Pharmaceuticals
AVIR
$363M
| – | – |
-35
| Closed | – | – |
|
2963
Avantis Short-Term Fixed Income ETF
AVSF
$640M
| – | – |
-1,480
| Closed | -$71.7K | – |
|
2964
Avalo Therapeutics
AVTX
$644M
| – | – |
0
| – | – |
2020 Q1
8 quarters
|
|
2965
Anavex Life Sciences
AVXL
$137M
| $0 | ﹤0.01% |
17
-78
| -82% | -$959 |
2021 Q2
3 quarters
|
|
2966
Dauch Corp
DCH
$1.21B
| $0 | ﹤0.01% |
19
-31
| -62% | -$264 |
2021 Q2
3 quarters
|
|
2967
Axsome Therapeutics
AXSM
$8.47B
| – | – |
-92
| Closed | -$3K | – |
|
2968
DELISTED
Azul
AZUL
| $0 | ﹤0.01% |
4
| – | – |
2020 Q1
8 quarters
|
|
2969
Invesco Taxable Municipal Bond ETF
BAB
$858M
| $0 | ﹤0.01% |
16
| – | – |
2018 Q4
13 quarters
|
|
2970
Atlanta Braves Holdings Series A
BATRA
$3.51B
| $0 | ﹤0.01% |
11
-25
| -69% | -$675 |
2020 Q2
7 quarters
|
|
2971
BridgeBio Pharma
BBIO
$13.1B
| – | – |
-121
| Closed | -$2K | – |
|
2972
BioCryst Pharmaceuticals
BCRX
$2.05B
| $0 | ﹤0.01% |
+9
| New | +$144 |
2022 Q1
0 quarters
|
|
2973
Bicycle Therapeutics
BCYC
$252M
| $0 | ﹤0.01% |
5
| – | – |
2021 Q4
1 quarter
|
|
2974
Belden
BDC
$4.07B
| $0 | ﹤0.01% |
3
-2
| -40% | -$115 |
2021 Q4
1 quarter
|
|
2975
KE Holdings
BEKE
$19.6B
| – | – |
-19
| Closed | – | – |
|
Similar funds
Parallel Advisors's Q1 2022 Portfolio in Review
As of Q1 2022, Parallel Advisors held 3,473 positions worth $2.52B, down 6.4% from $2.69B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Parallel Advisors's Q1 2022 filing shows 218 new, 908 increased, 1,467 reduced and 292 closed positions. Its largest new stake was eFFECTOR Therapeutics, Inc. Common Stock: 27,098 shares worth $2.74M. The largest sale was Vanguard ESG US Stock ETF, an estimated $9.63M.
By sector, the portfolio is most concentrated in Miscellaneous at 51% of assets, down from 51% a quarter earlier, followed by Technology and Financials.
- Parallel Advisors's largest Q1 2022 buy was eFFECTOR Therapeutics, Inc. Common Stock: 27,098 shares worth $2.74M.
- Parallel Advisors added most to iShares Fallen Angels USD Bond ETF in Q1 2022, an estimated $9.31M increase.
- Parallel Advisors's biggest Q1 2022 reduction was Vanguard ESG US Stock ETF, cutting an estimated $9.63M.
- Parallel Advisors fully exited State Street SPDR Nuveen ICE Short Term Municipal Bond ETF in Q1 2022, selling an estimated $1.09M.
- Parallel Advisors's ten largest holdings make up 37% of its $2.52B portfolio in Q1 2022.
- Parallel Advisors opened 218 new positions and closed 292 in Q1 2022.
- Parallel Advisors's portfolio value fell 6.4% quarter-over-quarter to $2.52B.
Based on Parallel Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.